Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma

Table 1 Main clinical and molecular characteristics of the cohort of 21 patients with symptomatic (MM).

PT	Sex	Age	Diagnosis	State	High bone disease	Osteolysis	High risk	Adenosine (µmol/L)	ISS
A.MG	F	55	MM	D	YES	YES	YES	22.00	III
A.M.	F	69	MM	R	YES	YES	NO	74.20	III
B.FL.	M	70	MM	D	NO	NO	NO	69.88	II
B.FA.	M	57	MM	D	YES	YES	NO	62.17	I
B.R.	F	71	MM	R	YES	YES	-	110.28	III
C.M.	F	74	MM	D	NO	YES	YES	119.89	III
C.MG.	F	60	MM	D	NO	NO	NO	45.37	II
C.I.	F	74	MM	D	NO	NO	YES	55.61	III
G.A.	F	76	MM	D	NO	YES	-	56.96	II
M.A.	F	76	MM	D	YES	YES	NO	62.37	I
M.MV.	F	86	MM	R	YES	YES	NO	39.26	II
M.E.	M	90	MM	R	YES	YES	-	165.10	III
M.U.	M	57	MM	D	YES	YES	NO	129.78	III
M.G.	M	65	MM	D	NO	NO	YES	62.73	III
M.M.	F	69	MM	D	NO	YES	-	39.26	I
O.C.	F	86	MM	D	YES	YES	YES	78.21	III
S.M.G.	M	53	MM	D	YES	YES	YES	113.00	III
V.F.	F	77	MM	D	NO	NO	NO	155.23	III
X.I.	F	79	MM	D	YES	YES	YES	210.84	III
Z.EC.	F	77	MM	R	YES	YES	-	45.99	III
Z.F.	F	68	MM	D	YES	YES	NO	107.81	II

Analysis of MM patients included: (i) International staging system (ISS); (ii) Presence of >3 osteolytic lesions or fractures are defined as high bone disease; (iii) Patients (PT) with either del(17p), t(4;14) or t(14;16) were considered to be at high cytogenetic risk and at standard risk otherwise; (iv) Adenosine concentrations (µmol/L) measured at diagnosis (D) or relapse (R).

ISSN: 1528-3658